← Stack Research Tool

Pair page

GHK-Cu with Rigin

Mechanism-tag overlap and published literature for GHK-Cu and Rigin, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.

Mechanism overlap

Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.

GHK-CU RIGIN 2 UNIQUE TAGS 1 UNIQUE TAGS 0 SHARED
GHK-Cu unique connective-tissuecopper-tripeptide-skin
Shared none
Rigin unique cosmetic-immune-modulating-tetrapeptide

Co-administration notes from the literature

Verbatim summary text pulled from each compound's profile data. Researchers studying GHK-Cu and Rigin have published these mechanism-level observations. Not a co-administration recommendation.

Evidence level: mechanistic only

GHK-Cu complements Rigin through independent signal-peptide remodeling activity (collagen, elastin, glycosaminoglycan upregulation) and copper-enzyme cofactor biology. The two peptides are mechanistically parallel rather than overlapping. Practical formulation note: GHK-Cu may produce blue-green color that complicates finished-product aesthetics.

Quick facts

GHK-Cu

RouteTopical > SubQ
Half-lifeMinutes (plasma); longer topical residence
FDA statusCosmetic ingredient; Category 2 for injection
WADANot specifically named; plausibly S0 by analogy
Full GHK-Cu profile →

Rigin

RouteTopical only
Half-lifeNot listed
FDA statusCosmetic ingredient
WADANot banned
Full Rigin profile →

Literature table

Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.

Year Compound Source Finding
1995GHK-CuBuffoni F, Pino R, Dal Pozzo A. Effect of tripeptide-copper complexes on the process of healing of cutaneous wounds in mice. Arch Int Pharmacodyn Ther. 1995;330(3):345-360. PMID: 9060874. PMID 9060874preclinical, in vivo
1993GHK-CuMaquart FX, Bellon G, Chaqour B, Wegrowski J, Patt LM, Trachy RE, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺ in rat experimental wounds. J Clin Invest. 1993;92(5):2368-2376. PMID: 8227353. PMID 8227353preclinical, in vivo
2011GHK-CuHostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflamm Res. 2011;60(1):79-86. PMID: 20835751. PMID 20835751preclinical, in vitro
2007GHK-CuPyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834-839. PMID: 17702486. PMID 17702486preclinical, in vitro
1988GHK-CuMaquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺. FEBS Lett. 1988;238(2):343-346. PMID: 3169264. PMID 3169264preclinical, in vitro
2017GHK-CuPickart L, Vasquez-Soltero JM, Margolina A. The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline. Brain Sci. 2017;7(2):20. PMID: 28212278. PMID 28212278mechanism / discovery
2012GHK-CuCampbell JD, McDonough JE, Zeskind JE, Hackett TL, Pechkovsky DV, Brandsma CA, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Med. 2012;4(8):67. PMID: 22937864. PMID 22937864mechanism / discovery
1973GHK-CuPickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243(124):85-87. PMID: 4351857. (Original discovery publication.) PMID 4351857mechanism / discovery
2026GHK-CuWADA Prohibited List 2026. World Anti-Doping Agency. wada-ama.org.regulatory / registry
2025GHK-CuFDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025-2026.regulatory / registry
2018GHK-CuPickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. PMID: 29986520. doi:10.3390/ijms19071987. (Comprehensive modern review.) PMID 29986520research article
2015GHK-CuPickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. PMID: 26236730. PMID 26236730research article
2002RiginBlanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303-310. PMID: 18498523. (Foundational cosmetic peptide characte… PMID 18498523mechanism / discovery
2021RiginFerreira MSM, Sousa Lobo JM, Almeida IF. Usage of Synthetic Peptides in Cosmetics for Sensitive Skin. Pharmaceuticals (Basel). 2021;14(8):702. PMID: 34358128. (Review of cosmetic peptide use in sensitive-skin formulations, with mechanistic discussion of palmitoyl tetrapeptide-7'… PMID 34358128review
2020RiginFerreira MS, Magalhães MC, Sousa Lobo JM, Almeida IF. Trending Anti-Aging Peptides. Cosmetics. 2020;7(4):91. doi:10.3390/cosmetics7040091. (Review of the current cosmetic peptide landscape with detailed discussion of palmitoyl tetrapeptide-7 mechanism claims.)review
2012RiginReddy BY, Jow T, Hantash BM. Bioactive oligopeptides in dermatology: Part I. Exp Dermatol. 2012;21(8):563-568. PMID: 22672785. (Review of bioactive oligopeptides in dermatology including cosmetic palmitoyl-conjugate peptides.) PMID 22672785review
2009RiginZhang L, Falla TJ. Cosmeceuticals and peptides. Clin Dermatol. 2009;27(5):485-494. PMID: 19695480. (Cosmeceutical peptide review discussing palmitoyl tetrapeptide-7 positioning within the signal / neurotransmitter / carrier peptide framework.) PMID 19695480review
2006RiginMaggio M, Guralnik JM, Longo DL, Ferrucci L. Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci. 2006;61(6):575-584. PMID: 16799139. (Foundational review of IL-6 in aging — the biological plausibility case for Rigin's anti-inflammagi… PMID 16799139review
2005RiginLupo MP. Cosmeceutical peptides. Dermatol Surg. 2005;31(7 Pt 2):832-836; discussion 836. PMID: 16029675. (Widely cited academic review of the cosmeceutical peptide class including signal peptides, neurotransmitter-acting peptides, and carrier peptides.) PMID 16029675review
1987RiginRocchi R, Biondi L, Filira F, Gobbo M, Dagan S, Fridkin M. Synthesis and biological activity of tuftsin and rigin derivatives containing monosaccharides or monosaccharide derivatives. Int J Pept Protein Res. 1987;29(2):250-261. PMID: 3570655. (Classic synthesis and biological ch… PMID 3570655industry documentation
2020RiginErrante F, Ledwoń P, Latajka R, Rovero P, Papini AM. Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Front Chem. 2020;8:572923. PMID: 33195067. (Cosmetic peptide overview referencing palmitoyl tetrapeptide-7 within the broader framework of synthetic cosm… PMID 33195067research article
2018RiginFranceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14(10):576-590. PMID: 30046148. (Inflammaging framework citation — the broader biological context for cosmetic anti-infla… PMID 30046148research article
2015RiginHoppel M, Reznicek G, Kählig H, Kotisch H, Resch GP, Valenta C. Topical delivery of acetyl hexapeptide-8 from different emulsions: Influence of emulsion composition and internal structure. Eur J Pharm Sci. 2015;68:27-35. PMID: 25433250. (Methodologically adjacent cosmetic peptid… PMID 25433250research article
2009RiginGorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327-345. PMID: 19570043. (Cosmetic peptide topical-delivery review — stratum corneum penetration, palmitoyl conjugate strategy, and mechanism-by-mechanism evidence i… PMID 19570043research article

Related pair pages

More research context

Frequently asked

Have GHK-Cu and Rigin been studied together?

Researchers have published mechanistic-level co-administration discussion of GHK-Cu and Rigin. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.

What mechanisms do GHK-Cu and Rigin share?

GHK-Cu and Rigin do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.

What is the FDA status of GHK-Cu and Rigin?

GHK-Cu: Cosmetic ingredient; Category 2 for injection. Rigin: Cosmetic ingredient. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.

Where can I find the full research on GHK-Cu and Rigin?

Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the GHK-Cu profile and the Rigin profile. The Kalios Stack Research Tool hub lists every compound covered.

Last updated: April 2026